Some analysts estimate that more than 100 incretin-modulating candidates, across GLP-1, GIP, glucagon, amylin, and novel multi-agonist combinations, are now in development. Over 50 companies are vying for a slice of this opportunity, from biotechnology newcomers to multinational giants. …
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
The 'Dispatched' Podcast - Episode 1, Series 5
January 23, 2026 - - Podcast -
AusBiotech announces new advisory groups to support the life sciences sector
January 22, 2026 - - Latest News -
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 - - Latest News -
New funding deal brings next-generation cystic fibrosis treatments closer for New Zealanders
January 22, 2026 - - Latest News -
For almost all of the last 40 years, Governments have aimed to make medicines less affordable, for everyone but them
January 22, 2026 - - Latest News -
argenx deepens Australian research footprint with Monash partnership
January 21, 2026 - - Latest News -
New data reinforce promise of cancer vaccine, with Australia playing a key role
January 21, 2026 - - Latest News